In August 2023, a Riley Hospital for Children patient became the first child in Indiana to receive teplizumab, a groundbreaking therapy that delays the onset of stage 3 type 1 diabetes by an average of three years. The treatment received Federal Drug Administration approval in November 2022, three years after Indiana University School of Medicine researchers conducted clinical trials and published data that helped lead to the FDA’s decision.